USD 2.51
(-5.64%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 | 3.06 Million USD | -49.13% |
2023 | 6.03 Million USD | -6.33% |
2022 | 6.44 Million USD | 27.89% |
2021 | 5.03 Million USD | 24.52% |
2020 | 4.04 Million USD | 42.32% |
2019 | 2.84 Million USD | 60.64% |
2018 | 1.76 Million USD | 149.25% |
2017 | 709.81 Thousand USD | 21.37% |
2016 | 584.84 Thousand USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q3 | -3.28 Million USD | -134.44% |
2024 Q1 | 4.82 Million USD | 0.63% |
2024 Q4 | -3.28 Million USD | 0.0% |
2024 FY | 2.64 Million USD | -56.14% |
2024 Q2 | 9.53 Million USD | 97.65% |
2023 Q2 | 1.24 Million USD | 106.69% |
2023 Q4 | 4.79 Million USD | 104.67% |
2023 Q3 | 2.34 Million USD | 88.86% |
2023 Q1 | 600 Thousand USD | 107.11% |
2023 FY | 6.03 Million USD | -6.33% |
2022 Q1 | 1.54 Million USD | 113.83% |
2022 Q4 | -8.44 Million USD | -577.82% |
2022 Q2 | 3.21 Million USD | 108.12% |
2022 Q3 | 1.76 Million USD | -45.07% |
2022 FY | 6.44 Million USD | 27.89% |
2021 Q3 | 1.95 Million USD | 276.25% |
2021 Q4 | -11.17 Million USD | -671.18% |
2021 FY | 5.03 Million USD | 24.52% |
2021 Q2 | 519.78 Thousand USD | 36.32% |
2021 Q1 | 381.29 Thousand USD | -96.06% |
2020 Q2 | 2.06 Million USD | 103.77% |
2020 Q3 | 3.86 Million USD | 87.43% |
2020 FY | 4.04 Million USD | 42.32% |
2020 Q1 | 1.01 Million USD | -64.43% |
2020 Q4 | 9.67 Million USD | 150.46% |
2019 Q1 | 676.36 Thousand USD | 32.11% |
2019 FY | 2.84 Million USD | 60.64% |
2019 Q3 | 731.08 Thousand USD | -45.92% |
2019 Q2 | 1.35 Million USD | 99.85% |
2019 Q4 | 2.84 Million USD | 288.74% |
2018 FY | 1.76 Million USD | 149.25% |
2018 Q3 | 1.25 Million USD | 313.59% |
2018 Q4 | 511.98 Thousand USD | -59.28% |
2018 Q1 | 303.98 Thousand USD | 186.8% |
2018 Q2 | 303.98 Thousand USD | 0.0% |
2017 Q4 | 105.99 Thousand USD | 0.0% |
2017 FY | 709.81 Thousand USD | 21.37% |
2016 FY | 584.84 Thousand USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bright Green Corporation | 8.25 Million USD | 62.811% |
Alpha Teknova, Inc. | 45.85 Million USD | 93.307% |
ANI Pharmaceuticals, Inc. | 195.98 Million USD | 98.434% |
Aquestive Therapeutics, Inc. | 44.85 Million USD | 93.157% |
Collegium Pharmaceutical, Inc. | 159.2 Million USD | 98.072% |
Cosmos Health Inc. | 26.18 Million USD | 88.277% |
Journey Medical Corporation | 54.59 Million USD | 94.378% |
Embecta Corp. | 528.4 Million USD | 99.419% |
Esperion Therapeutics, Inc. | 271.89 Million USD | 98.871% |
Dynavax Technologies Corporation | 219.14 Million USD | 98.599% |
Intra-Cellular Therapies, Inc. | 590 Million USD | 99.48% |
Pacira BioSciences, Inc. | 326.37 Million USD | 99.06% |
PainReform Ltd. | 9.58 Million USD | 67.976% |
Sunshine Biopharma, Inc. | 13.12 Million USD | 76.615% |
Sunshine Biopharma, Inc. | 13.12 Million USD | 76.615% |
SCYNEXIS, Inc. | 51.84 Million USD | 94.08% |
Safety Shot Inc | 12.1 Million USD | 74.655% |
Procaps Group, S.A. | 199.47 Million USD | 98.461% |
Theratechnologies Inc. | 72.75 Million USD | 95.782% |
Harrow Health, Inc. | 89.97 Million USD | 96.589% |
Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | 67.508% |
Biofrontera Inc. | 39.95 Million USD | 92.319% |
DURECT Corporation | 43.71 Million USD | 92.979% |
Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 99.42% |
Cronos Group Inc. | 96.7 Million USD | 96.826% |
OptiNose, Inc. | 85.1 Million USD | 96.394% |
Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 98.678% |
Kala Pharmaceuticals, Inc. | 39.15 Million USD | 92.161% |
RedHill Biopharma Ltd. | -9.56 Million USD | 132.101% |
Organogenesis Holdings Inc. | 314.13 Million USD | 99.023% |
Guardion Health Sciences, Inc. | 9.73 Million USD | 68.459% |
Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 92.869% |
Radius Health, Inc. | 265.92 Million USD | 98.846% |
Universe Pharmaceuticals INC | 13.84 Million USD | 77.827% |
ProPhase Labs, Inc. | 37.85 Million USD | 91.892% |
Phibro Animal Health Corporation | 260.29 Million USD | 98.821% |
Procaps Group S.A. | 187.24 Million USD | 98.361% |
Alvotech | 285.43 Million USD | 98.925% |
TherapeuticsMD, Inc. | 9.82 Million USD | 68.761% |
Viatris Inc. | 5.96 Billion USD | 99.949% |
Rockwell Medical, Inc. | 15.37 Million USD | 80.037% |
Aytu BioPharma, Inc. | 59.84 Million USD | 94.871% |
SIGA Technologies, Inc. | 22.04 Million USD | 86.076% |
Tilray Brands, Inc. | 251.35 Million USD | 98.779% |
Lifecore Biomedical, Inc. | 49.03 Million USD | 93.741% |
Shineco, Inc. | 17.94 Million USD | 82.9% |
PetIQ, Inc. | 192.72 Million USD | 98.407% |
Regencell Bioscience Holdings Limited | 3.99 Million USD | 23.1% |
Incannex Healthcare Limited | 30.05 Million USD | 89.787% |
Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.808% |
Alimera Sciences, Inc. | 62.64 Million USD | 95.1% |
Silver Spike Investment Corp. | 762.49 Thousand USD | -302.521% |
Assertio Holdings, Inc. | 368.58 Million USD | 99.167% |
Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | 47.852% |
Petros Pharmaceuticals, Inc. | 17.8 Million USD | 82.766% |
Clever Leaves Holdings Inc. | 21.16 Million USD | 85.501% |
Cyclo Therapeutics, Inc. | 21.04 Million USD | 85.414% |
Avadel Pharmaceuticals plc | 164.96 Million USD | 98.14% |
Hempacco Co., Inc. | 7.59 Million USD | 59.597% |
Talphera, Inc. | 11.99 Million USD | 74.411% |
Alvotech | 285.43 Million USD | 98.925% |
Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 97.819% |
Lantheus Holdings, Inc. | 344.9 Million USD | 99.11% |
Currenc Group, Inc. | 24 Million USD | 87.213% |
Kamada Ltd. | 45.42 Million USD | 93.244% |
Indivior PLC | 911 Million USD | 99.663% |
Evoke Pharma, Inc. | 12.4 Million USD | 75.268% |
Flora Growth Corp. | 10.57 Million USD | 70.988% |
Cyclo Therapeutics, Inc. | 21.04 Million USD | 85.414% |
Evolus, Inc. | 189.75 Million USD | 98.383% |
HUTCHMED (China) Limited | 436.23 Million USD | 99.296% |
Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 98.009% |
Akanda Corp. | 3.48 Million USD | 11.894% |